Found: 99
Select item for more details and to access through your institution.
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 5, p. 1052, doi. 10.1007/s10637-019-00731-5
- By:
- Publication type:
- Article
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 669, doi. 10.1007/s10637-012-9857-z
- By:
- Publication type:
- Article
TNF-blockade in patients with advanced hormone refractory prostate cancer.
- Published in:
- 2011
- By:
- Publication type:
- Report
Association of pretreatment neutrophil-to-lymphocyte ratio ( NLR) and overall survival ( OS) in patients with metastatic castration-resistant prostate cancer ( mCRPC) treated with first-line docetaxel.
- Published in:
- BJU International, 2014, v. 114, n. 6b, p. E11, doi. 10.1111/bju.12531
- By:
- Publication type:
- Article
Is There a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
- Published in:
- Cancer Research & Treatment, 2016, v. 48, n. 1, p. 281, doi. 10.4143/crt.2014.289
- By:
- Publication type:
- Article
Mortality Following Prostate Cancer Recurrence After Radical Prostectomy—Reply.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy.
- Published in:
- JAMA: Journal of the American Medical Association, 2005, v. 294, n. 4, p. 433, doi. 10.1001/jama.294.4.433
- By:
- Publication type:
- Article
The Role of Cytotoxic Chemotherapy in Prostate Cancer: A Critical Reevaluation 20 Years Later.
- Published in:
- Oncology (08909091), 2006, v. 20, n. 14, p. 1854
- By:
- Publication type:
- Article
Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens.
- Published in:
- 2008
- By:
- Publication type:
- Letter
RESPONSE.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2001, v. 93, n. 15, p. 1175
- By:
- Publication type:
- Article
Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221100022
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate- Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with 18F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on ProstateSpecific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide .
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPvL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate- Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 33, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.259069
- By:
- Publication type:
- Article
Detection of Early Progression with <sup>18</sup>F‐DCFPyL PET/CT in Men with Metastatic Castration‐Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 2, p. 1, doi. 10.2967/jnumed.120.259226
- By:
- Publication type:
- Article
Comparison of Prostate-Specific Membrane Antigen-Based <sup>18</sup>F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 1, p. 46, doi. 10.2967/jnumed.115.163782
- By:
- Publication type:
- Article
Biodistribution, Tumor Detection, and Radiation Dosimetry of <sup>18</sup>F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2012, v. 53, n. 12, p. 1883, doi. 10.2967/jnumed.112.104661
- By:
- Publication type:
- Article
Test–retest repeatability of organ uptake on PSMA‐targeted <sup>18</sup>F‐DCFPyL PET/CT in patients with prostate cancer.
- Published in:
- Prostate, 2023, v. 83, n. 12, p. 1186, doi. 10.1002/pros.24577
- By:
- Publication type:
- Article
Lack of repeatability of radiomic features derived from PET scans: Results from a <sup>18</sup>F‐DCFPyL test–retest cohort.
- Published in:
- Prostate, 2023, v. 83, n. 6, p. 547, doi. 10.1002/pros.24483
- By:
- Publication type:
- Article
Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805.
- Published in:
- Prostate, 2022, v. 82, n. 12, p. 1176, doi. 10.1002/pros.24369
- By:
- Publication type:
- Article
Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. e1179, doi. 10.1002/onco.13803
- By:
- Publication type:
- Article
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
- Published in:
- Oncologist, 2016, v. 21, n. 10, p. 1212, doi. 10.1634/theoncologist.2015-0428
- By:
- Publication type:
- Article
Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib.
- Published in:
- Oncologist, 2014, v. 19, n. 1, p. 51, doi. 10.1634/theoncologist.2012-0335
- By:
- Publication type:
- Article
Unmet Needs in the Prediction and Detection of Metastases in Prostate Cancer.
- Published in:
- Oncologist, 2013, v. 18, n. 5, p. 549, doi. 10.1634/theoncologist.2013-0027
- By:
- Publication type:
- Article
Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram.
- Published in:
- Oncologist, 2012, v. 17, n. 12, p. 1508, doi. 10.1634/theoncologist.2012-0125
- By:
- Publication type:
- Article
Natural History of Progression After PSA Elevation Following Radical Prostatectomy.
- Published in:
- JAMA: Journal of the American Medical Association, 1999, v. 281, n. 17, p. 1591, doi. 10.1001/jama.281.17.1591
- By:
- Publication type:
- Article
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.
- Published in:
- World Journal of Urology, 2019, v. 37, n. 12, p. 2623, doi. 10.1007/s00345-018-2477-2
- By:
- Publication type:
- Article
Tumour-infiltrating Gr-1<sup>+</sup> myeloid cells antagonize senescence in cancer.
- Published in:
- Nature, 2014, v. 515, n. 7525, p. 134, doi. 10.1038/nature13638
- By:
- Publication type:
- Article
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.
- Published in:
- BJU International, 2012, v. 110, n. 11b, p. E575, doi. 10.1111/j.1464-410X.2012.11286.x
- By:
- Publication type:
- Article
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
- Published in:
- BJU International, 2012, v. 109, n. 1, p. 32, doi. 10.1111/j.1464-410X.2011.10422.x
- By:
- Publication type:
- Article
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
- Published in:
- BJU International, 2011, v. 108, n. 3, p. 378, doi. 10.1111/j.1464-410X.2010.09878.x
- By:
- Publication type:
- Article
Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease.
- Published in:
- BJU International, 2008, v. 102, n. 11, p. 1539, doi. 10.1111/j.1464-410X.2008.07877.x
- By:
- Publication type:
- Article
Long-term effects of androgen deprivation therapy in prostate cancer patients.
- Published in:
- Clinical Endocrinology, 2002, v. 56, n. 6, p. 779, doi. 10.1046/j.1365-2265.2002.01551.x
- By:
- Publication type:
- Article
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 269, p. 1, doi. 10.1126/scitranslmed.3010563
- By:
- Publication type:
- Article
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 17, p. 2684, doi. 10.1002/cncr.28767
- By:
- Publication type:
- Article
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.
- Published in:
- 2013
- By:
- Publication type:
- journal article